Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits

Merck & Co’s Marshall To Take Over

Executive Summary

A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.

You may also be interested in...



New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal

Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.

No Cash Boost For Novartis From Sandoz Spin-Off

After a lengthy review, Novartis has confirmed Sandoz will be a publicly traded standalone company listed on the SIX Swiss Exchange, although CEO Vas Narasimhan says he will still consider bids for the division.

Dunad Bags Big Pharma Partner In Protein Degradation Deal With Novartis

Dunad is out-licensing its targeted protein degradation and covalent drug platform to Novartis in a deal that could be worth up to $1.3bn.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel